HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd.
(Nasdaq: CGEN), a clinical-stage cancer immunotherapy company
and a leader in predictive target discovery, announced today that
the Company will release its second quarter 2021 financial results
on Wednesday, July 28, 2021 before
the U.S. financial markets open. Management will host a conference
call and webcast to review the results and provide a corporate
update at 8:30 AM ET.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will also be available
via live webcast through Compugen's website, located at the
following link
Following the live audio webcast, a replay will be available on
the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable, predictive
computational discovery platforms to identify novel drug targets
and develop therapeutics in the field of cancer immunotherapy.
Compugen's lead product candidate, COM701, a first-in-class
anti-PVRIG antibody, for the treatment of solid tumors, is
undergoing Phase 1 single, dual and triple combination studies. In
addition, COM902, Compugen's antibody targeting TIGIT, is in a
Phase 1 clinical study. Compugen's therapeutic pipeline also
includes early stage immuno-oncology programs focused largely on
myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at www.cgen.com
Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen
Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2021-results-on-wednesday-july-28-2021-301333441.html
SOURCE Compugen Ltd.